SENNA, Gianenrico
 Distribuzione geografica
Continente #
NA - Nord America 4.026
AS - Asia 3.260
EU - Europa 2.991
SA - Sud America 513
AF - Africa 70
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 10.867
Nazione #
US - Stati Uniti d'America 3.959
SG - Singapore 1.403
CN - Cina 964
IT - Italia 659
GB - Regno Unito 499
BR - Brasile 440
HK - Hong Kong 436
RU - Federazione Russa 405
FR - Francia 309
DE - Germania 305
IE - Irlanda 259
SE - Svezia 255
FI - Finlandia 131
VN - Vietnam 123
KR - Corea 120
IN - India 42
JP - Giappone 38
CA - Canada 32
UA - Ucraina 31
NL - Olanda 29
AR - Argentina 26
MX - Messico 26
TG - Togo 26
TR - Turchia 23
ID - Indonesia 22
BD - Bangladesh 21
BE - Belgio 20
AT - Austria 19
ZA - Sudafrica 18
ES - Italia 15
PL - Polonia 15
VE - Venezuela 10
EC - Ecuador 9
IQ - Iraq 9
MA - Marocco 8
SA - Arabia Saudita 8
CH - Svizzera 7
PY - Paraguay 7
UZ - Uzbekistan 7
CL - Cile 6
CO - Colombia 6
JO - Giordania 6
KE - Kenya 6
NO - Norvegia 6
PE - Perù 6
AZ - Azerbaigian 5
LT - Lituania 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
CZ - Repubblica Ceca 3
JM - Giamaica 3
KG - Kirghizistan 3
LV - Lettonia 3
NP - Nepal 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AU - Australia 2
BG - Bulgaria 2
EG - Egitto 2
EU - Europa 2
IL - Israele 2
LB - Libano 2
LK - Sri Lanka 2
MG - Madagascar 2
OM - Oman 2
SN - Senegal 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BJ - Benin 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
KZ - Kazakistan 1
MD - Moldavia 1
MY - Malesia 1
MZ - Mozambico 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
SI - Slovenia 1
TH - Thailandia 1
TL - Timor Orientale 1
TT - Trinidad e Tobago 1
Totale 10.866
Città #
Dallas 705
Singapore 641
Chandler 626
Hong Kong 430
Southend 422
Dublin 255
New York 229
Beijing 208
Ashburn 189
Jacksonville 158
Woodbridge 145
Verona 120
Lawrence 109
Princeton 109
Wilmington 90
Munich 89
Los Angeles 80
The Dalles 80
Houston 77
Ann Arbor 75
Sindelfingen 74
Jinan 60
Buffalo 58
Helsinki 53
Shenyang 53
Milan 48
Redondo Beach 48
Columbus 47
Nanjing 39
Redmond 37
Hebei 36
Bologna 35
Guangzhou 33
Rome 32
Tokyo 32
São Paulo 30
Boardman 28
Turku 28
Redwood City 27
Changsha 26
Hanoi 26
Ho Chi Minh City 26
Seattle 26
Lomé 25
Ningbo 25
Kent 23
Haikou 22
Tianjin 22
Nanchang 21
Norwalk 21
Dong Ket 20
London 19
Nuremberg 19
Taizhou 19
Rio de Janeiro 18
San Francisco 18
Santa Clara 18
Taiyuan 18
Brussels 17
Naples 17
Zhengzhou 17
Amsterdam 16
Hangzhou 16
Padova 14
Jakarta 13
Warsaw 13
Boston 12
Brooklyn 12
Council Bluffs 12
Johannesburg 12
Seoul 12
Chennai 11
Frankfurt am Main 11
Lanzhou 11
Mexico City 11
Bari 10
Jiaxing 10
Toronto 10
Chicago 9
Curitiba 9
Falls Church 9
Lancaster 9
Lappeenranta 9
Moscow 9
Palermo 9
Porto Alegre 9
Stockholm 9
Treviso 9
Belo Horizonte 8
Brasília 8
Turin 8
Vienna 8
Boydton 7
Falkenstein 7
Roubaix 7
Tashkent 7
Villarbasse 7
Catania 6
Delhi 6
Detroit 6
Totale 6.479
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 310
Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database 163
La salute del respiro: epidemiologia, costi sanitari ed implicazioni sociali delle malattie respiratorie croniche in Europa e in Italia 142
Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and hymenopteria allergy 142
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 136
Allergy and the bone: unexpected relationships 120
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 120
Study on the Immunoreactivity of Triticum monococcum (Einkorn) Wheat in Patients with Wheat-Dependent Exercise-Induced Anaphylaxis for the Production of Hypoallergenic Foods 119
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 119
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management 118
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels 117
Allergic rhinitis: pharmacotherapy in pregnancy and old age 116
A double-blind placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects 115
Periostin: The bone and beyond 115
Analysis of the positivity rate in IgE positive patients to inhalant allergens in Verona Hospital Laboratory during 2002-2003 111
Adverse reaction to local anaesthetics: Is it always allergy? 110
Impatto socio-sanitario e livello del controllo delle patologie respiratorie croniche ostruttive e della rinite in Italia 106
Fatal asthma; is it still an epidemic? 105
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 104
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 102
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 100
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 99
Scombroid syndrome: it seems to be fish allergy but... it isn't 98
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 93
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 91
Is hymenoptera venom allergy an occupational disease? 90
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 90
What lies beyond Asthma Control Test: Suggestions for clinical practice 89
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 89
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 88
Potential benefit of omalizumab in respiratory diseases 87
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 87
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 86
Systemic Reactions After Hymenoptera Sting And Raised Serum Tryptase Strongly Suggest Clonal Mast Cells Disorders 85
How much specific is the association between hymenoptera venom allergy and mastocytosis? 85
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 85
Biologics and global burden of asthma: A worldwide portrait and a call for action 85
Asthma management among different specialists: results from a national Italian survey 84
Omalizumab management beyond clinical trials: the added value of a network model 83
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 83
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 83
Wasp venom allergy screening with recombinant allergen testing. Diagnostic performance of rPol d 5 and rVes v 5 for differentiating sensitization to Vespula and Polistes subspecies 81
IgE to staphylococcal enterotoxins are undetectable in sera from patients with nasal polyposis 81
Anaphylaxis and intimate behaviour 81
Uncontrolled Asthma: Unmet Needs in the Management of Patients 81
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 80
Residual Lung Function Impairment Is Associated with Hyperventilation in Patients Recovered from Hospitalised COVID-19: A Cross-Sectional Study 79
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 78
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 78
The degree of serological sensitization to cat allergen in patients with or without cat at home 77
Biologic Therapy in a Patient with Asthma and Nasal Polyps 77
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 77
Immunoblotting study of specific antibody patterns against latex and banana 76
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 75
COPD prevalence in a north-eastern Italian general population 75
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 73
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 73
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis 72
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 71
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 71
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 71
Treatment with American Polistes venom was ineffective in an Italian patient allergic to European Polistes 70
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 70
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 70
Evaluation of the IgE cross-reactions among vespid venoms. A possible approach for the choice of immunotherapy 69
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? 69
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 69
Biologic Therapy in a Patient with Asthma and Nasal Polyps 69
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 69
Asthma management among allergists in Italy: results from a survey 69
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 69
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 69
BCG vaccination and COVID-19: Much ado about nothing? 69
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice 68
Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation 68
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 68
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 68
Targeting eosinophils: severe asthma and beyond 67
Effect of α1 Antitrypsin Deficiency on Lung Volume Decline in Severe Asthmatic Patients Undergoing Biologic Therapy 66
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 65
Prevalence and features of asthma-chronic obstructive pulmonary disease overlap in Northern Italy general population 65
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 65
One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response 65
Oral health in asthmatic patients: a review: Asthma and its therapy may impact on oral health 64
Multidisciplinary management in type 2 inflammatory disease 64
Sex in Respiratory and Skin Allergies 63
Emerging drugs for allergic conjunctivitis 63
Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? 62
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 62
Biologics for the Treatments of Allergic Conditions 61
Allergen-specific immunotherapy and COVID-19: What happened? 60
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 60
Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry 60
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials 59
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach 58
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 57
Orphan immunotherapies for allergic diseases 57
Spontaneous pneumomediastinum complicating severe acute asthma exacerbation in adult patients 57
Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology 57
The role of the pharmacy in the management of bronchial asthma: A literature-based evaluation 56
Totale 8.493
Categoria #
all - tutte 51.291
article - articoli 50.344
book - libri 411
conference - conferenze 191
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 345
Totale 102.582


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021438 0 0 0 92 118 71 17 31 21 8 50 30
2021/2022712 85 172 19 45 16 14 15 48 50 13 51 184
2022/20231.855 139 158 190 266 179 421 31 108 222 15 86 40
2023/20241.347 52 95 121 169 115 283 89 63 20 59 192 89
2024/20253.211 160 182 152 447 124 100 119 255 499 237 264 672
2025/20262.204 689 642 726 147 0 0 0 0 0 0 0 0
Totale 11.087